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Abstract
Background—Two doses of measles-mumps-rubella (MMR) vaccine are 97% effective against 
measles, but waning antibody immunity and two-dose vaccine failures occur. We administered a 
third MMR dose (MMR3) to young adults and assessed immunogenicity over 1 year.
Methods—Measles virus (MeV) neutralizing antibody concentrations, cell-mediated immunity 
(CMI), and IgG antibody avidity were assessed at baseline, 1-month, and 1-year after MMR3.
Results—Of 662 subjects at baseline, 1 (0.2%) was seronegative (<8 mIU/mL) and 23 (3.5%) 
had low (8-120 mIU/mL) MeV neutralizing antibodies. At 1-month post-MMR3, 1 (0.2%) subject 
was seronegative and 6 (0.9%) had low neutralizing antibodies with only 21/662 (3.2%) showing a 
≥4-fold rise in neutralizing antibodies. At 1-year post-MMR3, none were negative and 10 (1.6%) 
of 617 subjects had low neutralizing antibodies. CMI results showed low-levels of spot-forming 
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cells after stimulation, suggesting T-cell memory, but the response was minimal post-MMR3. 
MeV IgG avidity results did not correlate with neutralization results.
Conclusions—Most subjects were seropositive pre-MMR3 and very few had a secondary 
immune response post-MMR3. Similarly, CMI and avidity results showed minimal qualitative 
improvements in immune response post-MMR3. We did not find compelling data to support a 
routine third dose of MMR vaccine.
Keywords
measles; third dose measles-mumps-rubella (MMR) vaccine; measles vaccine immunogenicity; 
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avidity
Background
Measles is a contagious, viral rash illness; complications including pneumonia and 
encephalitis can result in death[1]. High two-dose measles-mumps-rubella (MMR) 
vaccination coverage and improved measles control in the World Health Organization 
(WHO) Region of the Americas resulted in the declaration of measles elimination in the 
U.S. in 2000[2].
Two doses of MMR vaccine are generally sufficient to provide long-lasting protection 
against measles[3]. Nonetheless, measles virus (MeV) is one of three components in the 
MMR vaccine, and third doses have been administered during mumps outbreaks among 
highly vaccinated populations[4, 5] and in non-outbreak settings among healthcare 
personnel, military recruits, international travelers, and college students who may have been 
two-dose vaccinated but lacked documentation[6-8].
The immunogenicity of the MeV component of a third MMR dose has not been studied. We 
assessed the magnitude and duration of an aggregate MeV neutralizing antibody response, 
cell-mediated immune response, and IgG antibody avidity before and after a third MMR 
dose (MMR3) in a healthy, young adult population.
Methods
Setting
The study population comprised patients of the Marshfield Clinic, a private, multispecialty 
group practice with regional centers throughout central and northern Wisconsin. The Clinic 
maintains an electronic vaccination registry (www.recin.org) for immunizations 
administered by Marshfield Clinic providers, local public health agencies, and immunization 
providers. No measles cases were reported in the area during the study period.
Subjects
Two cohorts comprising 685 subjects were enrolled during 2009-2010. Cohort 1 (N=113 
subjects) participated in a 10-year longitudinal study at the Marshfield Clinic examining 
immunogenicity and adverse events following the second MMR vaccine dose, hereafter 
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called the longitudinal study[9, 10]. To achieve adequate sample size, Marshfield's 
vaccination registry was used to recruit subjects from Cohort 2 who had two documented 
MMR doses but did not participate in the longitudinal study (N=572 subjects). Invitation 
letters were mailed to both cohorts and follow-up phone calls were made. Additionally, 
Cohort 1 subjects who participated in the measles cell-mediated immunity (CMI) sub-study 
during the longitudinal study were asked to participate in the current CMI sub-study.
Although only 16 (14.2%) Cohort 1 subjects had low or negative MeV antibody 
concentrations during the longitudinal study, 93/113 Cohort 1 subjects with ≥1 low or 
negative antibody concentration to measles, mumps, or rubella during the longitudinal study 
(defined previously[10-12]) and all Cohort 2 subjects were offered a third dose of MMR 
vaccine (M-M-R II; Merck & Co.). Serum was collected from all subjects immediately 
before (baseline), and one month and one year after MMR3.
Study design
At each visit, subjects were questioned about measles disease, exposures, vaccinations, and 
other health events. MMR vaccine was administered during the initial visit. Informed 
consent was obtained from all subjects. Institutional Review Boards of the Marshfield Clinic 
Research Foundation and the Centers for Disease Control and Prevention approved the 
study. Sample size determination and exclusion criteria were previously described[13].
Cell-mediated immunity sub-study
The 60 participants of the longitudinal measles CMI sub-study or subjects with a low or 
negative MeV antibody concentration on ≥1 serum specimen draw during the longitudinal 
study were asked to participate in the current CMI sub-study. However, only 34 (56.7%) 
subjects meeting these criteria were re-enrolled. A convenience sample from Cohort 2 was 
used to reach the recruitment goal of 60 subjects.
Laboratory Methods
Laboratory testing was performed at the end of the study. Other than each subject's unique 
identifier code and serum collection dates, laboratories were blinded to study information.
Plaque reduction neutralization—Plaque reduction neutralization (PRN) testing was 
performed using low-passage Edmonston MeV on Vero cell monolayers, as previously 
described[14]. Endpoints were determined for all serum samples tested and ND50 titers 
calculated using the Kärber method. Serial four-fold dilutions of serum were tested in 
duplicate starting at 1:8 and ending at 1:8192 against virus diluted to give 25-35 plaques/
well and run in parallel with the Second WHO International Standard Reference Serum 
(66/202). After incubating the virus-serum mixtures at 37° C with 5% CO2, the mixtures 
were transferred onto corresponding 24-well tissue culture plates containing confluent Vero 
monolayers; after incubating for 1 hour at 37° C, the inoculum was removed and cells 
overlaid with medium containing carboxymethylcellulose and returned to the incubator for 5 
days prior to staining with neutral red and plaque counting. Serum samples from individual 
subjects were tested in the same assay run. Titers were standardized against the WHO 
reference serum with a titer of 1:8 corresponding to 8 mIU/mL in this assay.
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Cell-mediated immunity—Cryo-preserved peripheral blood mononuclear cells (PBMCs) 
were thawed and cultured overnight in 5% CO2 at 37°C with Roswell Park Memorial 
Institute (RPMI) media supplemented with 4% human serum type AB (Lonza), 1% 
penicillin/streptomycin, and 1% 200 mM L-glutamine. Following the overnight culture, 
IFN-γ production by T-cells was assessed using enzyme-linked immunospot assays of 
PBMCs (5×105 cells/well), as previously described[15]. PBMCs were stimulated either with 
a mixture of MeV hemagglutinin, fusion, and nucleoprotein proteins as 20 amino acid 
peptides (11 amino acids overlapping) at 1μg/mL or with a lysate from MeV-infected Vero 
cells (Advanced Biotechnologies) at 10μg/mL for 40 hours. RPMI media and Con A 
(5μg/mL) were used as negative and positive controls, respectively. After stimulation, the 
plates were incubated with biotin-conjugated antibodies to human IFN-γ, then developed 
and read, as previously described[15]. Low and positive T-cell responses were categorized as 
<20 and ≥20 spot-forming cells (s.f.c.)/million PBMCs, respectively.
Avidity—MeV IgG antibody avidity was evaluated to determine whether there was a 
correlation between neutralizing antibody concentrations and strength of antibody binding. 
Avidity testing occurred after neutralization results were available using the method 
described previously[16]. Serum samples from all 662 subjects were split into quartiles 
based on baseline PRN antibody concentration. Subjects with negative neutralizing antibody 
concentrations were negative for MeV IgG by the Captia Measles IgG enzyme immunoassay 
assay (Trinity Biotech, Jamestown, NY), thus avidity could not be measured. All subjects 
with low MeV neutralizing antibody concentrations at baseline, 1-month, or 1-year post-
MMR3 were tested for MeV antibody avidity. A random number generator selected 
specimens from at least 10 subjects from each of the remaining 3 quartiles for avidity testing 
of 59 subjects. The specimen was classified as negative if at 1:21 dilution it had undetectable 
IgG by the Captia assay, low avidity if the end titer avidity index percentages (etAI%) were 
≤30%, intermediate between 30%-70% (intermediate results were retested), or high avidity 
if the etAI% was ≥70%.
Data analysis
Based on previous studies[17, 18], serum samples were categorized as: (1) negative (<8 
mIU/mL), susceptible to infection and disease; (2) low (8-120 mIU/mL), potentially 
susceptible to infection and disease; (3) medium (121-900 mIU/mL), potentially susceptible 
to infection but not disease; and (4) high (>900 mIU/mL), not susceptible to infection or 
disease. Serum samples were also dichotomized as potentially susceptible (<121 mIU/mL) 
and not susceptible (≥121 mIU/mL).
We combined Cohorts 1 and 2 during analysis because there were no statistically significant 
differences between the cohorts by sex, race/ethnicity, or age. However, Cohort 1 had 
significantly lower geometric mean concentrations (GMCs) of MeV neutralizing antibody at 
baseline (p=0.0289), so we stratified the chi-squared risk factor analysis at 1-month and 1-
year post-MMR3 by baseline MeV neutralizing antibody concentrations.
Mantel-Haenszel chi-squared and Fisher's exact tests were run to assess categorical 
variables. Wilcoxon Rank Sum tests were used for continuous variables. Potential risk 
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factors for negative or low MeV neutralizing antibody levels included: sex, age at first MMR 
dose, time since second MMR dose (we used <15 years versus ≥15 years prior based on 
average age of subjects at enrollment minus the age when the second dose was 
recommended), and (for post-MMR3 serum samples) the binary variable of whether the 
subject had low or negative MeV neutralizing antibody levels at baseline. In multivariate 
logistic regression, a backwards selection approach that used p-values <0.4 for inclusion and 
<0.05 for retention identified factors independently associated with negative or low MeV 
neutralizing antibody levels at baseline, 1-month and 1-year post-MMR3.
For the CMI analysis, the mean number of spot-forming cells resulting from PBMC 
stimulation with MeV peptide and MeV lysate was determined at baseline, 1-month, and 1-
year post-MMR3. The MeV-specific T-cell response was calculated by subtracting the mean 
spontaneous response (no stimulation) from the mean peptide or lysate response. MeV T-cell 
responses were correlated with MeV neutralizing antibody levels at baseline, 1-month, and 
1-year post-MMR3. For the avidity analysis, end titer avidity index percentages were 
correlated with MeV neutralizing antibody levels at all 3 time points.
GMCs of MeV neutralizing antibody were calculated from base 2 log-transformed data. 
Statistical significance was assigned for P-values <0.05. Data were analyzed with SAS 9.3 
(Cary, NC). Reverse cumulative distribution curves were created in Excel to compare the 
shift in curves from baseline, 1-month, and 1-year post-MMR3.
Results
Enrollment
We contacted 194/200 persons from the longitudinal study; 113 (58.2%) were enrolled, 45 
(23.2%) refused, and 36 (18.5%) were ineligible (15 had previously received MMR3 and 21 
had other reasons). To achieve adequate sample size, we contacted 1379 (76.8%) of an 
additional 1795 persons. Of those, 572 (41.4%) were enrolled, 664 (48.2%) refused, and 143 
(10.4%) were ineligible (4 had previously received MMR3 and 139 had other reasons)
(Supplementary Figure 1).
Baseline serum samples were obtained from 685 enrolled subjects. We excluded 20 (2.9%) 
Cohort 1 subjects who had medium or high antibody concentrations for all 3 antigens 
throughout the longitudinal study and were, therefore, not given MMR3. An additional 3 
(0.4%) were excluded because they only had baseline samples. There were 662 (96.6%) 
subjects who received MMR3 and completed the 1-month draw; 617 (92.6%) completed the 
1-year draw. Subjects were aged 18-28 years, (mean: 20.8 years, standard deviation: +/-2.1); 
294 (44.4%) were male and 649 (98.0%) were self-declared non-Hispanic, white. The mean 
interval between the second and third MMR doses was 15.8 years (range: 6.7–20.4 years).
MeV neutralizing antibody concentrations pre- and post-MMR3
Of 662 subjects at baseline, 1 (0.2%) was seronegative, 23 (3.5%) had low MeV neutralizing 
antibody concentrations, 337 (50.9%) had medium concentrations, and 301 (45.5%) had 
high concentrations (Figure 1). The seronegative subject was a female aged 20 years who 
received her last MMR dose 18 years prior. At 1-month and 1-year post-MMR3, she had 
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medium MeV neutralizing antibody concentrations. Of 23 subjects with low baseline 
antibody concentrations, 1 was negative, 5 were low, 14 were medium, and 3 were high 1-
month post-MMR3. One year post-MMR3, 19 of 23 had sera drawn; 5 had low, 14 had 
medium, and 0 had high MeV neutralizing antibody concentrations.
Overall, at 1-month post-MMR3, 1/662 (0.2%) subjects had no detectable MeV neutralizing 
antibodies, 6 (0.9%) had low, 256 (38.7%) had medium, and 399 (60.3%) had high 
neutralizing antibody concentrations. One year post-MMR3, all 617 subjects who returned 
were positive for MeV neutralizing antibodies: 10 (1.6%) had low, 299 (48.5%) had 
medium, and 308 (49.9%) had high neutralizing antibody concentrations.
When assessed as a continuous variable, subjects with low or negative baseline MeV 
neutralizing antibody concentrations were more likely to have low or negative antibody 
concentrations 1-month and 1-year post-MMR3. Whereas subjects with high baseline 
concentrations were more likely to have high neutralizing antibody concentrations at 1 
month (R2=0.54, P<0.0001) and 1 year (R2=0.68, P<0.0001)(Figure 2).
GMCs were significantly different between baseline and 1-month post-MMR3 (727 vs. 1060 
mIU/mL, P<0.0001), and between baseline and 1-year post-MMR3 (727 vs. 843 mIU/mL, 
P<0.05). However, the reverse cumulative distribution curves show the shift in MeV 
antibody concentrations from baseline to 1-month to 1-year post-MMR3 was minimal 
(Figure 3).
Four-fold rises
Twenty-one (3.2%) of 662 subjects had ≥4-fold rises from baseline to 1-month post-MMR3, 
of whom at baseline 1 was seronegative, 8 had low antibody concentrations, and 12 had 
medium PRN concentrations. Eight (1.3%) of 617 subjects had ≥4-fold rises from baseline 
to 1-year post-vaccination, of whom at baseline 1 was seronegative, 4 had low 
concentrations, and 3 had medium PRN concentrations.
Risk factors for negative or low MeV neutralizing antibody concentrations pre- and post-
MMR3
The unadjusted odds ratios showed that those who had their first MMR dose at age 12-<15 
months ([Odds Ratio] OR:3.47, [Confidence Interval] CI:1.24–9.72, p=0.01) had a higher 
odds of having lower or negative baseline antibody concentrations compared with those who 
had their first dose at age ≥15 months, and those who had their second MMR dose <15 years 
prior had a lower odds of having low or negative baseline MeV neutralizing antibody levels 
versus those who had their second dose ≥15 years prior (OR:0.22, CI:0.05–0.93, p=0.03)
(Table 1).
Of 50 (7.6%) subjects who received their first dose at age 12-<15 months, 5 (10.0%) had 
negative or low baseline MeV antibody concentrations, versus 19/612 (3.1%) subjects who 
were vaccinated with their first dose at age ≥15 months. Of 190 (28.7%) subjects who 
received their second dose <15 years prior, 2 (1.1%) had negative or low baseline MeV 
antibody concentrations, versus 22/472 (4.7%) subjects who received their second dose ≥15 
years prior. In multivariate analysis, having the first MMR dose at 12-<15 months of age 
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remained a significant risk factor at baseline (OR:3.94,CI:1.37–11.30, p=0.01), and those 
who had their second MMR dose <15 years prior continued to have a lower odds of having 
low or negative MeV antibody concentrations (OR:0.18,CI:0.04–0.80, p=0.02).
At 1-month post-MMR3, there were no significant risk factors for having low or negative 
MeV antibody concentrations when adjusting the chi-squared analysis by controlling for 
baseline GMCs. In multivariate analysis, a significant risk factor for negative or low MeV 
antibody concentrations 1-month post-MMR3 was whether a subject had low or negative 
baseline MeV antibody concentrations (OR:195.8,CI:21.8–>999.9, p<0.0001).
At 1-year post-MMR3, females had a lower odds of having low or negative MeV antibodies 
(OR:0.34, CI:0.06–1.80, p=0.04) versus males when adjusting the chi-squared analysis by 
controlling for baseline GMCs. In multivariate analysis at 1-year post-MMR3, being female 
remained protective (OR:0.19, CI:0.04–0.99, p=0.049) and low or negative baseline MeV 
neutralizing antibody concentrations were a risk factor (OR:54.95, CI:10.90–277.14, 
p<0.0001).
Cell-mediated immunity
Of 60 CMI sub-study subjects, 7 were excluded (6 did not receive MMR3 and 1 had 
insufficient blood drawn); 1 (1.9%) of 53 subjects missed the 1-month draw and 6 (11.3%) 
missed the 1-year draw. MeV lysate stimulation results were missing for an additional 2 
subjects at baseline and 1 subject at 1 month. Positive controls were positive for all CMI 
subjects, indicating viable cells capable of spot-formation. The unstimulated T-cell mean 
spot-forming cells (s.f.c.)/million PBMCs was 0.1±0.1 at baseline, 0.1±0.1 at 1-month, and 
0.2±0.2 at 1-year post-MMR3.
Of 53 CMI sub-study subjects, none had negative baseline MeV neutralizing antibody 
concentrations and 5 (9.4%) had low baseline concentrations, of whom, 1 had a positive 
baseline CMI response (≥20 s.f.c./million PBMCs) to peptide stimulation and none had a 
positive baseline response to lysate stimulation. Only 13/48 (27.1%) subjects with medium 
or high baseline MeV neutralizing antibodies had a positive baseline CMI result by peptide 
stimulation and 7/46 (15.2%) subjects had a positive baseline CMI result by lysate 
stimulation.
The spot-forming cells/million PBMCs were generally higher with peptide stimulation 
compared to lysate stimulation. At baseline, the MeV peptide mean spot-forming cells was 
19.6±9.3 s.f.c./million PBMCs compared to 11.9±7.2 s.f.c./million PBMCs by lysate 
stimulation. At 1-month post-MMR3, the MeV peptide mean spot-forming cells was 
18.5±7.6 s.f.c./million PBMCs, with 13/52 (25.0%) specimens positive by peptide 
stimulation, compared with 7.3±2.9 s.f.c./million PBMCs, with 5/51 (9.8%) specimens 
positive by lysate stimulation. At 1-year post-MMR3, the mean spot-forming cells was 
29.7±15.9 s.f.c./million PBMCs, with 14/47 (29.8%) positive by peptide stimulation, 
compared with 10.3±6.4 s.f.c./million PBMCs, with 7/47 (14.9%) specimens positive by 
lysate stimulation.
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Baseline MeV antibody concentrations did not correlate with baseline MeV T-cell responses 
to peptide stimulation (R2=0.002, p=0.73) or lysate stimulation (R2=0.0008, p=0.85)(Figure 
4). MeV antibody concentrations at 1-month post-MMR3 correlated with MeV T-cell 
responses at 1 month by peptide stimulation (R2=0.30, p<0.0001), but the correlation did not 
remain after removing the 2 outliers (R2=0.05, p=0.13). There was no correlation between 
MeV antibody concentrations and lysate stimulation at 1 month (R2=0.001, p=0.80), but 
after removing the outlier, there was a correlation (R2=0.14, p=0.007). At 1-year post-
MMR3, there was a significant correlation between MeV antibody concentrations and MeV 
T-cell responses by peptide stimulation (R2=0.17, p=0.004), but no correlation by lysate 
stimulation (R2=0.06, p=0.09).
Avidity
Overall, 38/59 (64.4%) subjects evaluated had MeV antibodies with high avidity at baseline 
(Table 2), including 7/24 (29.2%) subjects with low MeV antibody concentrations at 
baseline. The avidity results did not correlate with MeV antibody concentrations at baseline 
(R2=0.07, p=0.07), 1-month (R2=0.01, p=0.50) or 1-year (R2=0.02, p=0.31) post-MMR3 
(Figure 5).
Discussion
A modest but significant boost in MeV geometric mean neutralizing antibody concentrations 
occurred 1-month and 1-year post-MMR3 compared with baseline. However, almost all 
subjects were MeV seropositive prior to receiving MMR3, and subjects' antibody levels 
returned to near-baseline 1-year post-vaccination. Nonetheless, for the 24 (3.6%) subjects 
with low or negative baseline MeV antibody concentrations, 18 (75%) moved into medium 
or high categories at 1 month, of whom, 12 (67%) remained medium or high at 1 year. 
Among the subsets tested for CMI and avidity, we did not find compelling qualitative data to 
support a routine third dose of MMR vaccine.
The second MMR vaccine dose was recommended to provide measles immunity to 
individuals who failed to respond to the first dose[19]; two doses are 97% effective at 
preventing measles[20, 21]. Although 95% of vaccinated persons have detectable MeV 
antibodies 10-15 years after the second MMR dose[10, 22], waning immunity occurs after 
two doses[10][23], and two-dose failures have been documented[24].
Having a low or negative baseline MeV antibody concentration was the biggest risk factor 
for low or negative antibody concentrations 1-month and 1-year post-MMR3, suggesting 
that inherent biology may be partially responsible for a person's measles antibody levels[10, 
25]. Although our results concurred with other reports that timing of administration of the 
first and second MMR doses significantly affected MeV antibody levels later in life[26, 27], 
our findings represented only a small proportion of the study population (only 50 [7.6%] 
subjects received their first dose at age 12-<15 months).
Most subjects did not have a positive CMI result at baseline, despite the majority of subjects 
having medium or high baseline MeV antibody concentrations. Nonetheless, low-levels of 
spot-forming cells generally occurred for most specimens after stimulation, suggesting T-
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cell memory. However, this was not greatly boosted by MMR3. After removing outliers, we 
found mixed results at 1-month post-MMR3 with no correlation between MeV antibody 
response and MeV T-cell response by peptide stimulation, but a significant correlation by 
lysate stimulation. Although we did find a significant correlation between CMI response by 
peptide stimulation and MeV antibody concentration at 1-year post-MMR3, <1/3 of subjects 
had positive cell-mediated responses by peptide stimulation and even fewer had positive 
responses by lysate stimulation at 1 year. These findings could have been because transient 
increases in circulating MeV-specific T-cells were missed due to specimen collection timing 
(antigen-stimulated T-cell responses typically peak 2 weeks post-vaccination[28], whereas 
samples were taken 1-month and 1-year post-MMR3). Other studies assessing antibody and 
T-cell responses after a second MMR dose showed no correlation[29, 30]. Another 
possibility is that numbers of T-cells producing IFN-γ in response to MeV did not increase 
post-MMR3 due to lack of infection by vaccine virus in the presence of neutralizing 
antibodies.
The MeV IgG avidity results did not correlate with neutralization results. Most subjects 
reached an IgG avidity plateau. Typically, IgG avidity maturation for measles shifts from 
low to high 4 months following immunization or infection[16] which might negate 
additional increases in antibody avidity with subsequent doses of measles-containing 
vaccine. Nonetheless, only 29% of subjects with low baseline MeV neutralizing antibody 
concentrations had high avidity results at baseline. It could be interpreted that subjects with 
poor antibody response and intermediate avidity results were potentially susceptible prior to 
revaccination. However, the avidity results are an average of the measles IgG and should be 
interpreted cautiously, since whole MeV is used as the target antigen in the avidity assay, 
whereas the neutralization assay measures antibodies that bind MeV surface 
glycoproteins[31].
Our study had additional limitations. Subjects were not representative of the U.S. 
population. Selection bias may have occurred in Cohort 1, because MMR3 was only offered 
to those who had a low or negative measles, mumps, or rubella antibody concentration 
during the longitudinal study.
Overall, MeV neutralizing antibody concentrations initially increased after MMR3 but 
declined to near-baseline levels one year later. Although our findings showed that MMR3 
increased antibody levels for the small percentage of subjects with low MeV neutralizing 
antibody concentration levels who were on the cusp of protection, the CMI and avidity 
results in the subset tested showed that MMR3 did not result in substantial improvements in 
the quality of the immune response. While a third MMR dose may successfully immunize 
the rare individual who failed to respond after two doses, MMR3 is unlikely to solve the 
problem of waning immunity in the U.S. A better strategy for maintaining U.S. measles 
elimination would be to improve vaccination coverage in pockets of unvaccinated 
individuals and maintain high two-dose coverage nationally with the current two-dose MMR 
recommendation.
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Figure 1. 
Flow chart of measles virus neutralizing antibody concentration levels at baseline, 1 month, 
and 1 year following a third dose of MMR vaccine.
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Figure 2. 
A. Comparison of individual measles antibody concentration levels at baseline and 1 month 
following a third dose of MMR vaccine. R2=0.54, p<0.0001. B. Comparison of individual 
measles antibody concentration levels at baseline and 1 year following a third dose of MMR 
vaccine. R2=0.68, p<0.0001. For both figures, data points are represented by circles and they 
show the comparison result for each subject. The dark solid line represents the best-fit of the 
comparison. The light shading around the line represents the 95% confidence limits. The 
dotted lines represent 95% prediction limits.
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Figure 3. 
Reverse cumulative distribution curve by percent of subjects who had measles virus 
neutralizing antibody concentrations at baseline, 1 month, and 1 year following a third dose 
of MMR vaccine.
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Figure 4. 
Figure 4a: A. Comparison of baseline measles virus neutralizing antibody concentration 
levels (mIU/mL) and baseline measles virus T-cell response to measles virus peptide 
stimulation (spot-forming cells [s.f.c.]/ million cells), n= 53. R2= 0.002, p=0.73. B. 
Comparison of measles virus neutralizing antibody concentration levels (mIU/mL) and 
measles virus T-cell response to measles virus peptide stimulation (s.f.c./ million cells) 1 
month after receiving a third dose of MMR vaccine, n=50. R2=0.05, p=0.13 (Note that 2 
outliers were removed from the figure). When the 2 outliers were included, the results were: 
n=52. R2= 0.30, p<0.0001, and the x-axis on the graph extended beyond 40,000 mIU/mL. C. 
Comparison of measles virus neutralizing antibody concentration levels (mIU/mL) and 
measles virus T-cell response to measles virus peptide stimulation (s.f.c./ million cells) 1 
year after receiving a third dose of MMR vaccine, n=47. R2= 0.17, p=0.004. For all figures, 
data points are represented by circles and they show the comparison result for each subject. 
The dark solid line represents the best-fit of the comparison. The light shading around the 
line represents the 95% confidence limits. The dotted lines represent 95% prediction limits.
Figure 4b: A. Comparison of baseline measles virus neutralizing antibody concentration 
levels (mIU/mL) and baseline measles virus T-cell response to measles virus lysate 
stimulation (s.f.c./ million cells), n=51. R2= 0.0008, p=0.85. B. Comparison of measles virus 
neutralizing antibody concentration levels (mIU/mL) and measles virus T-cell response to 
measles virus lysate stimulation (s.f.c./ million cells) 1 month after receiving a third dose of 
MMR vaccine, n=49. R2= 0.14, p=0.007 (Note that 1 outlier was removed from the figure; 
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the other outlier was already missing because of insufficient blood drawn to analyze the 
measles virus lysate response). When the outlier was included, the results were: n=50. 
R2=0.001, p=0.80, and the x-axis on the graph extended beyond 40,000 mIU/mL. C. 
Comparison of measles virus neutralizing antibody concentration levels (mIU/mL) and 
measles virus T-cell response to measles virus lysate stimulation (s.f.c./ million cells) 1 year 
after receiving a third dose of MMR vaccine, n=47. R2=0.06, p=0.09. For all figures, data 
points are represented by circles and they show the comparison result for each subject. The 
dark solid line represents the best-fit of the comparison. The light shading around the line 
represents the 95% confidence limits. The dotted lines represent 95% prediction limits.
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Figure 5. 
A. Comparison of baseline measles virus neutralizing antibody concentration levels 
(mIU/mL) and baseline measles virus antibody avidity levels (end titer avidity index 
percentage [etAI%]), n= 51. R2=0.07, p=0.07. B. Comparison of measles virus neutralizing 
antibody concentration levels (mIU/mL) and measles virus antibody avidity levels (etAI%) 1 
month after receiving a third dose of MMR vaccine, n=51. R2=0.01, p=0.50. C. Comparison 
of measles virus neutralizing antibody concentration levels (mIU/mL) and measles virus 
antibody avidity levels (etAI%) 1 year after receiving a third dose of MMR vaccine, n=47. 
R2=0.02, p=0.31. For all figures, data points are represented by circles and they show the 
comparison result for each subject. The dark solid line represents the best-fit of the 
comparison. The light shading around the line represents the 95% confidence limits. The 
dotted lines represent 95% prediction limits.
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ua
rtil
e 1
 is
 m
ore
 th
an
 fr
om
 th
e o
the
r 3
 qu
art
ile
s, b
eca
use
 w
e t
est
ed
 th
e a
v
id
ity
 o
n 
ev
er
y 
su
bje
ct 
wh
o h
ad
 a 
ne
ga
tiv
e 
o
r 
lo
w
 m
ea
sle
s n
eu
tra
liz
in
g 
an
tib
od
y 
co
nc
en
tra
tio
n 
du
rin
g 
at
 le
as
t 1
 
tim
e 
po
in
t. 
O
f n
ot
e,
 2
4 
of
 2
7 
su
bje
cts
 in
 Q
ua
rtil
e 1
 ha
d a
 ne
ga
tiv
e 
o
r 
lo
w
 b
as
el
in
e 
m
ea
sle
s a
nt
ib
od
y 
co
nc
en
tra
tio
n;
 th
e 
re
m
ai
ni
ng
 3
 su
bje
cts
 in
 Q
ua
rtil
e 1
 ha
d a
 m
ed
ium
 ne
utr
ali
zin
g a
nti
bo
dy
 co
nc
en
tra
tio
n a
t b
ase
lin
e (
bu
t w
er
e 
st
ill
 in
 th
e 
lo
w
es
t q
ua
rti
le
).
3 A
bb
re
v
ia
tio
ns
 u
se
d:
 G
M
C 
m
ea
ns
 G
eo
m
et
ric
 M
ea
n 
Co
nc
en
tra
tio
n,
 N
eg
 m
ea
ns
 n
eg
at
iv
e,
 In
t m
ea
ns
 in
te
rm
ed
ia
te
, M
iss
 m
ea
ns
 m
iss
in
g
4 T
he
 m
ea
n 
av
id
ity
 in
de
x
 e
x
cl
ud
es
 th
e 
ne
ga
tiv
e 
sp
ec
im
en
s b
y 
Ca
pt
ia
 M
ea
sle
s I
gG
 e
nz
ym
e 
im
m
un
oa
ss
ay
 si
nc
e 
av
id
ity
 c
ou
ld
 n
ot
 b
e 
ru
n 
on
 th
os
e 
sp
ec
im
en
s.
5 N
eg
at
iv
e 
m
ea
n
s 
th
at
 a
t 1
:2
1 
di
lu
tio
n,
 th
e 
sp
ec
im
en
 h
ad
 u
nd
et
ec
ta
bl
e 
Ig
G
 b
y 
th
e 
Ca
pt
ia
 M
ea
sle
s I
gG
 e
nz
ym
e 
im
m
un
oa
ss
ay
.
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